ANI Pharmaceuticals has launched of Lithium Carbonate Extended Release Tablets, 300mg, an authorized generic of Lithobid, which is used in the treatment of manic episodes of Bipolar Disorder. The annual U.S. market for lithium carbonate is approximately $19 million, per IMS Health.

“We are pleased to announce the launch of an authorized generic of our mature brand product Lithobid,” said Arthur Przybyl, president and chief executive officer, ANI. “This generic launch represents ANI’s 11th new product introduction in 2016 capping a substantial commercial portfolio expansion for the company this year. We look to continued commercial portfolio growth in 2017.”